Aurobindo Pharma receives USFDA approval for Mometasone Furoate Monohydrate nasal spray
The approved product has an estimated market size of US$ 44.5 million for the twelve months ending January 2024
The approved product has an estimated market size of US$ 44.5 million for the twelve months ending January 2024
Cyanocobalamin Nasal Spray (RLD Nascobal) had estimated annual sales of USD 69 million in the U.S. (IQVIA MAT Mar 2023)
The partnership will commercialize four nasal sprays with a combined Global IQVIA market size in excess of $400m
APF Futurity is made from polyolefin materials with no metal parts or recycling disruptors
This launch builds upon Hikma’s leading position as one of the largest US providers of nasally administered medicines used for treating seasonal allergies and advances its objective of growing its specialty business in the US
The study demonstrated that patients who received NONS had significant reduction in viral load within 24 hours, which was sustained over seven days of treatment.
Glenmark received manufacturing and marketing approval from DCGI for Nitric Oxide Nasal Spray (NONS) as part of accelerated approval process
Viraleze was developed for application in the nasal cavity to help reduce exposure to respiratory viruses, including SARS-CoV-2. The product is registered for sale in Europe and India, and available online in certain markets
In some countries such as France, Italy, Spain and the Balkan region, Menarini Group will lead the commercialisation effort, as part of an exclusive licensing agreement signed with Glenmark
Ipratropium Bromide Nasal Solution is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis
Subscribe To Our Newsletter & Stay Updated